The goal of this clinical trial is to learn if the use of MRI-guided asymmetric ultrahipofractionated irradiation (2 fractions with dose increase in the tumor areas and dose sparing in urethra, rectum and neurovascular bundles) produces similar results in terms of local control and complications to standard 5-fraction SBRT.

The implementation of Magnetic Resonance Image Guided Radiotherapy (MRgRT) into a Prostate Cancer Program aims to reproduce the results obtained with state-of-the-art brachytherapy or EBRT with the added advantage of convenience and lack of invasiveness.

Optimal Inclusion Criteria

• Patients with low to favorable intermediate-risk prostate cancer as per the NCCN stratification criteria .
• No prior radiation therapy to the target areas
• Expected patient survival >5 years
• Patient able to undergo a MRI exam

Cautionary Inclusion Criteria

• Suboptimal candidates for high-dose therapy such as elderly, frail patients or patients with large volume glands (i.e, >60cm3) or extensive TURP in the prior 6-12 months should be considered cautionary indications.
• Patients with higher risk but low volume disease not candidates for ENI may be treated on an individual basis

Exclusion Criteria

• Prior radiation therapy to the target areas
• Expected patient survival below 5 years
• Patient unable to undergo a MRI exam

On request

Jul 1st, 2025 to June 30, 2030

On request